biostudies-literatureUnknown7(3)Burra P<h4>Background & aims</h4>Conflicting data exist regarding optimal prophylaxis for HBV recurrence (HBV-R) after liver transplantation (LT), particularly in patients with hepatocellular carcinoma (HCC). We assessed current practices for HBV-R prophylaxis in Italy, evaluating rates, risk factors, and the clinical impact of HBV-R and HCC-R.<h4>Methods</h4>We performed a multicentric, retrospective study involving 20 Italian LT centers. All patients who underwent LT for HBV-related liver diseases between 2010 and 2021 were included. Logistic regression was used to identify predictors of HBV-R and HCC-R. Survival curves were estimated with the Kaplan-Meier method and compared with the log-rank test.<h4>Results</h4>We included 1,205 LT recipients (60.8% with HCC). HBV prophylaxis was prescribed JHEP reports : innovation in hepatology101278https://www.ebi.ac.uk/biostudies/studies/S-EPMC11876922biostudies-literatureLiver transplantation for HBV-related liver disease: Impact of prophylaxis for HBV on HCC recurrence.PMC11876922Burra PRusso FPTrapani SFornasiere EFerrarese AMarenco SAngeli PFagiuoli SLanza AGScandali GMameli LAghemo ASvegliati Baroni GZanetto ABattistella SManuli CToniutto PGiannini EPonziani FRDe Simone PPasulo LDonato MFFerri FFrassanito GGrossi PGiannelli VDe Maria NBhoori SLauterio AForastiere DBiolato MGhinolfi DLenci ITurco LMorelli MCMazzaferro VRendina MDe Carlis LVacca PGLionetti RMagro BPassigato NPiano SDi Benedetto CPagano DAngrisani DMartini SfalseLiver transplantation for HBV-related liver disease: Impact of prophylaxis for HBV on HCC recurrence.<h4>Background & aims</h4>Conflicting data exist regarding optimal prophylaxis for HBV recurrence (HBV-R) after liver transplantation (LT), particularly in patients with hepatocellular carcinoma (HCC). We assessed current practices for HBV-R prophylaxis in Italy, evaluating rates, risk factors, and the clinical impact of HBV-R and HCC-R.<h4>Methods</h4>We performed a multicentric, retrospective study involving 20 Italian LT centers. All patients who underwent LT for HBV-related liver diseases between 2010 and 2021 were included. Logistic regression was used to identify predictors of HBV-R and HCC-R. Survival curves were estimated with the Kaplan-Meier method and compared with the log-rank test.<h4>Results</h4>We included 1,205 LT recipients (60.8% with HCC). HBV prophylaxis was prescribed 2025-01-01T00:00:00Z2025 Mar2025-04-04T10:42:26.946Z2025-04-04T10:42:26.946ZS-EPMC118769224004112010.1016/j.jhepr.2024.101278